Personalizing evidence-based primary prevention with aspirin: individualized risks and patient preference

Circ Cardiovasc Qual Outcomes. 2011 May;4(3):260-2. doi: 10.1161/CIRCOUTCOMES.111.961136.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Aspirin / therapeutic use*
  • Cardiovascular Diseases / prevention & control*
  • Evidence-Based Medicine*
  • Humans
  • Patient Participation*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Primary Prevention*
  • Risk Assessment
  • Risk Factors
  • United States

Substances

  • Platelet Aggregation Inhibitors
  • Aspirin